381 related articles for article (PubMed ID: 34407475)
1. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy.
Yang A; Bai Y; Dong X; Ma T; Zhu D; Mei L; Lv F
Acta Biomater; 2021 Oct; 133():257-267. PubMed ID: 34407475
[TBL] [Abstract][Full Text] [Related]
2. In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant.
Zhang H; Zhang Y; Hu H; Yang W; Xia X; Lei L; Lin R; Li J; Li Y; Gao H
Small; 2023 Aug; 19(33):e2301041. PubMed ID: 37078903
[TBL] [Abstract][Full Text] [Related]
3. Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity.
Yang P; Song H; Qin Y; Huang P; Zhang C; Kong D; Wang W
Nano Lett; 2018 Jul; 18(7):4377-4385. PubMed ID: 29932335
[TBL] [Abstract][Full Text] [Related]
4. Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment.
Huo W; Yang X; Wang B; Cao L; Fang Z; Li Z; Liu H; Liang XJ; Zhang J; Jin Y
Biomaterials; 2022 Sep; 288():121722. PubMed ID: 35963815
[TBL] [Abstract][Full Text] [Related]
5. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
[TBL] [Abstract][Full Text] [Related]
6. Programmable Delivery of Immune Adjuvant to Tumor-Infiltrating Dendritic Cells for Cancer Immunotherapy.
Liu J; Li HJ; Luo YL; Chen YF; Fan YN; Du JZ; Wang J
Nano Lett; 2020 Jul; 20(7):4882-4889. PubMed ID: 32551705
[TBL] [Abstract][Full Text] [Related]
7. Hydrogel/nanoparticles-mediated cooperative combination of antiangiogenesis and immunotherapy.
Yang A; Sheng S; Bai Y; Xing G; Yu X; Zhu D; Mei L; Dong X; Lv F
Acta Biomater; 2022 Nov; 153():124-138. PubMed ID: 36179979
[TBL] [Abstract][Full Text] [Related]
8. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.
Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W
Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876
[TBL] [Abstract][Full Text] [Related]
9. Development of immune cell delivery system using biodegradable injectable polymers for cancer immunotherapy.
Yoshizaki Y; Horii K; Murase N; Kuzuya A; Ohya Y
Int J Pharm; 2024 Mar; 652():123801. PubMed ID: 38244647
[TBL] [Abstract][Full Text] [Related]
10. In Situ Vaccination with An Injectable Nucleic Acid Hydrogel for Synergistic Cancer Immunotherapy.
Wang F; Xie M; Huang Y; Liu Y; Liu X; Zhu L; Zhu X; Guo Y; Zhang C
Angew Chem Int Ed Engl; 2024 Jan; 63(4):e202315282. PubMed ID: 38032360
[TBL] [Abstract][Full Text] [Related]
11. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
13. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
14. Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.
Verma V; Kim Y; Lee MC; Lee JT; Cho S; Park IK; Min JJ; Lee JJ; Lee SE; Rhee JH
Oncotarget; 2016 Jun; 7(26):39894-39906. PubMed ID: 27223090
[TBL] [Abstract][Full Text] [Related]
15. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
[TBL] [Abstract][Full Text] [Related]
17. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
18. Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy.
Lei L; Huang D; Gao H; He B; Cao J; Peppas NA
Sci Adv; 2022 Nov; 8(47):eadc8738. PubMed ID: 36427310
[TBL] [Abstract][Full Text] [Related]
19. Self-Immolated Nanoadjuvant for In Situ Vaccination Immunotherapy of Colorectal Cancer.
Wang W; Zhu Q; Jin Y; Gao J; Li J; Zheng X; Gao W; Saeed M; Sheng W; Yu H
Adv Healthc Mater; 2023 Sep; 12(23):e2300524. PubMed ID: 37269141
[TBL] [Abstract][Full Text] [Related]
20. Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy.
Ji P; Sun W; Zhang S; Xing Y; Wang C; Wei M; Li Q; Ji G; Yang G
Adv Sci (Weinh); 2023 Aug; 10(22):e2301789. PubMed ID: 37222047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
